This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,439
Antibody levels after vaccination.
Safety of the study vaccines.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Espoo, Finland
GSK Investigational Site
Lahti, Finland
GSK Investigational Site
Oulu, Finland
GSK Investigational Site
Pori, Finland
GSK Investigational Site
Tampere, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Vantaa, Finland
GSK Investigational Site
Bayreuth, Bavaria, Germany
GSK Investigational Site
Bindlach, Bavaria, Germany
GSK Investigational Site
Bobingen, Bavaria, Germany
...and 44 more locations